NuPathe, Inc. (PATH) Reports Q1 Loss of $0.68

May 14, 2013 7:37 AM EDT
Get Alerts PATH Hot Sheet
Price: $52.70 -2.04%

Today's EPS Names:
TEDU, JOBS, HIVE, More
Trade Now! 
Join SI Premium – FREE
NuPathe, Inc. (NASDAQ: PATH) reported Q1 EPS of ($0.68), versus ($0.43) reported last year.

Research and development expenses were $2.0 million in the first quarter of 2013, compared with $3.5 million in the first quarter of 2012. The decrease was largely attributable to higher expenses in the 2012 period for clinical and manufacturing related activities as the Company prepared for the Zecuity NDA resubmission, as well as reduced compensation expenses in the 2013 period due to fewer headcount. Selling, general and administrative expenses were $3.0 million in the first quarter of 2013, compared with $2.4 million for the same period in 2012. The 2013 period increase was primarily attributable to a $1.1 million increase in non-cash stock compensation expense, partially offset by lower headcount and reduced commercial operations expenses.

Net cash used in operating activities for the three months ended March 31, 2013 was $3.9 million, primarily the result of spending for normal operating activities and continued development of ZECUITY. During this period NuPathe also used $0.5 million of cash in investing activities and $0.1 million in financing activities.

As of March 31, 2013, NuPathe had $18.0 million in cash and cash equivalents and working capital of $14.2 million, compared with $22.6 million in cash and cash equivalents and working capital of $19.8 million as of December 31, 2012. Management estimates that the Company's existing cash and cash equivalents will be sufficient to fund operations and debt service obligations into the fourth quarter of 2013.

For earnings history and earnings-related data on NuPathe, Inc. (PATH) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings